40 eligible patients with confirmed esophageal or gastric adenocarcinoma and anemia will be
randomized to a control or intervention group for management of this anemia. The control
group treatment will consist of standard treatments as governed by the clinical team (eg oral
iron, blood transfusions) whilst the intervention group will be treated with intravenous iron
III isomaltoside (Monofer ®).
It is hypothesized that intravenous iron supplementation is more efficacious than standard
therapies.